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In utero exposure to vinclozolin (VIN), an antiandrogenic fungicide, is linked to multigenerational pheno-
typic and epigenetic effects. Mechanisms remain unclear. We assessed the role of antiandrogenic activity
and DNA sequence context by comparing effects of VIN vs. M2 (metabolite with greater antiandrogenic
activity) and wild-type C57BL/6 (B6) mice vs. mice carrying mutations at the previously reported VIN-
responsive H19/Igf2 locus. First generation offspring from VIN-treated 8nrCG mutant dams exhibited
increased body weight and decreased sperm ICR methylation. Second generation pups sired by affected






treatments, B6 dams, 8nrCG sires or additional mutant lines were not similarly affected. Therefore, pup
response to VIN over two generations detected here was an 8nrCG-specific maternal effect, independent
of antiandrogenic activity. These findings demonstrate that maternal effects and crossing scheme play a
major role in multigenerational response to in utero exposures.NA methylation
. Introduction
Endocrine-disrupting compounds (EDCs) are environmental
ompounds that interfere with the homeostasis of the endocrine
ystem. EDC exposure is of growing concern because it is linked to
ncreased prevalence of human diseases such as cancer, diabetes,
besity, asthma, neurodegenerative disorders, and reproductive
isorders [1]. Furthermore, experimental models show that expo-
Abbreviations: VIN, Vinclozolin, or 3-(3,5-dichlorophenyl)-5-methyl-
-vinyloxazolidine-2,4-dione; EDC, Endocrine disrupting compound; M1,
-[[(3,5-dichlorophenyl)-carbamoyl]oxy]-2-methyl-3-butenoic acid; M2, 3′ ,5′-
ichloro-2-hydroxy-2-methylbut-3-enanilide; AR, Androgen Receptor; ER,
strogen Receptor; PR, Progesterone Receptor; GD, Gestational Day; PND, Postnatal
ay; AGD, Anogenital distance; DHT, Dihydrotestosterone; SRY, Sex determining
egion of the Y chromosome gene; ICR, Imprinting Control Region; BWS, Beckwith-
iedemann syndrome; DMR, Differentially methylated region; G0, Generation
ero, parental generation; G1, First generation; G2, Second generation.
∗ Corresponding author at: Department of Genetics, School of Medicine, University
f North Carolina at Chapel Hill, 120 Mason Farm Rd, CB#7264, Chapel Hill, NC 27599.
E-mail address: folami@email.unc.edu (F.Y. Ideraabdullah).
ttps://doi.org/10.1016/j.reprotox.2018.03.005 sure to EDCs in utero can negatively influence offspring health
outcomes over multiple generations [2]. Vinclozolin (VIN) is a dicar-
boximide fungicide that is still used commercially but in limited
application in the United States (US) due to adverse effects on male
reproduction detected in experimental models [3–5]. In rodents,
VIN exposure in utero disrupts male reproduction causing reduced
anogenital distance (AGD) and sperm count, cleft phallus, hypospa-
dias, ectopic testes, vaginal pouches, and epididymal granulomas
[6–8].
The mechanism by which VIN perturbs male reproduc-
tion is not fully understood. However, VIN and two of its
metabolites (M1 & M2) have been shown to compete with dihy-
drotestosterone (DHT) for binding the androgen receptor (AR)
and therefore may act in part by disrupting genomic activ-
ity of AR [9,10]. Compared to VIN and M1, M2 seemingly has
greater potential to interfere with AR activity. M2 was pre-
viously reported to have a greater ability to compete with
androgen for binding to AR (DHT (Ki = 100 nM) > hydroxyflutamide
(Ki = 175 nM) > testosterone (Ki = 220 nM) >M2 (Ki = 9.65 M) > M1




























































e a more potent antagonist of AR transcriptional activity, acting
t a dose that was more similar to hydroxyflutamide (a simi-
arly structured known antiandrogenic compound) [9]. VIN and its
etabolites have also been reported to interact with other steroid
eceptors. Here also, M2 was shown to be a more potent antagonist
f transcriptional activity of progesterone receptor (PR) and min-
ralocorticoid receptor (MR) and a more potent agonist of AR and
strogen receptors (ER)  and  [13–15].
VIN exposure in utero was the first reported model of transgen-
rational epigenetic inheritance. Male rats exposed to VIN in utero
xhibited adverse reproductive outcomes and altered DNA methy-
ation in sperm over 3 generations [8,16]. A separate study also
eported transgenerational DNA methylation changes at imprinted
oci including the H19/Igf2 imprinting control region (ICR) in mature
perm [17]. Genetic differences have been shown to influence her-
table responses to VIN in reports showing that transgenerational
ermline epimutations could be detected in outbred CD-1 mice but
ot inbred 129 mice [18]. Exact sequences responsible were not
nvestigated. The mechanism of persistence of VIN-induced pheno-
ypic and epigenetic changes are unclear. However, recent studies
how that VIN-induced methylation changes do not persist through
tages of reprogramming during male germ cell development [19]
uggesting an alternate mechanism of transmission.
Here, we used the VIN mouse exposure model to investigate fac-
ors that may contribute to differences in sensitivity to endocrine
isruptors. We used a two-stage study design to examine the role
f M2 metabolite availability (compared to VIN) and DNA sequence
ontext (wildtype vs. mutations at the H19/Igf2 ICR) in determining
he extent and heritability of epigenetic and phenotypic outcomes
n response to VIN. The mutant lines used, 8nrCG, 2,3 and IVS,
arry targeted mutations at the H19/Igf2 ICR that mimic genetic
utations found at the epigenetically perturbed human locus
n patients with the overgrowth disorder Beckwith-Wiedemann
yndrome (BWS) [20–26]. Aberrant H19/Igf2 expression is also
ssociated with metabolic disorders such as diabetes and obesity,
ilms tumor of the kidney, adrenocortical tumors, and various
ther forms of cancer [27–31]. The cause of H19/Igf2 epimutations
emains unknown, however, studies suggest the genetic mutations
ay act by disrupting epigenetic stability at the locus [22–26].
hile these mutations alone in the mouse do not perturb epi-
enetic status [20,21], this study will investigate whether the
resence of these mutations increase sensitivity to VIN-induced
pimutation.
. Materials and methods
.1. Animals – genetic line descriptions, sources, and housing
Animal handling was performed in accordance with the Guide
or the Care and Use of Laboratory Animals under the correspond-
ng animal use protocol at the University of North Carolina at
hapel Hill and housed at the David H. Murdock Institute Vivar-
um in Kannapolis, NC. Five mouse lines were used in the study
ncluding: (1) wild-type fully inbred C57BL/6 (B6) mice; (2) wild-
ype C7 mice homozygous for CAST/EiJ across chromosome 7 and
ixed CAST/EiJ-B6 genetic background [32]; (3) mutant 8nrCG
ice [20] carrying targeted mutation of 8 base pairs at 8 CpGs
t the H19/Igf2 locus; (4) mutant IVS mice [20] carrying a tar-
eted deletion of 0.9 kb at the H19/Igf2 imprinting control region;
nd (5) mutant 2,3 mice [21] carrying a targeted deletion of
.3 kb at the H19/Igf2 imprinting control region. All mutant lines
ere previously backcrossed 6–10 generations into B6 to result in
ostly (>98%) B6 genetic background as confirmed by genotyp-
ng. B6 mice were purchased from The Jackson Laboratory (Bar
arbor, ME) and used directly (study 1) or purchased separatelyand bred in-house to generate animals for study 2. B6-Cast7 (C7),
8nrCG, 2,3, and IVS were derived in Dr. Marisa Bartolomei’s
lab at the University of Pennsylvania [32,20,21], then transferred
and bred in-house at the David H. Murdoch Institute Vivarium in
Kannapolis to generate animals for study 1 and study 2. Steril-
ized water and rodent chow were fed ad libitum. All mice were
euthanized in accordance with current recommendations by the
American Veterinary Medical Association (AVMA) guidelines. All
tissues were collected and flash frozen in liquid nitrogen following
euthanasia.
2.2. Breeding and treatments (see Fig. 1 for specific cross
descriptions and timelines)
Supplemental Table 1 lists the number of pups, males, females,
litters (dams), and average number of males per litter assessed
in each experimental group. For generating G1 animals, G0
sires and dams (virgin females) were group housed after wean-
ing/purchasing and set up to breed at approximately 8–10 weeks
of age. Use of G0 C7 males allowed for consistency in paternal con-
tribution between lineages and also allowed for allelic expression
or methylation analyses should the data have shown significant
changes in the latter. G0 dams were bred to stud males (8–24
weeks of age) and checked for vaginal plugs every morning. The
first morning of a successful plug was considered GD1 and plugged
females were immediately separated from stud males and placed
into treatment cages. Group housed females were separated before
parturition to enable identification of each litter separately. G1 pups
were counted on the morning of birth to measure litter size, sexed
at PND5 to measure the number of males and females, weaned at
PND28, and euthanized at PND84. For deriving the second gener-
ation of animals (G2), 10 wk old G1 males and females treated in
utero were intercrossed (avoiding brother sister mating) or simul-
taneously outcrossed to untreated inbred B6 females. G2 pups were
counted on the morning of birth, sexed at PND5, and euthanized at
PND5.
All G0 dams were placed on a low-phytoestrogen purified diet
(Teklad, TD.95092) one-week prior to mating and throughout
breeding and gestation until PND5 to standardize nutrient intake
and minimize potential xenoestrogenic properties of soy based
diet [33]. Pregnant females were group-housed based on treatment
group and plug date and treated daily with either VIN (VIN) (analyt-
ical grade >99% purity, Chem Service Inc, PA), M2 (analytical grade
>99% purity, Cayman Chemical, MI), or pure corn oil (CON) (Sigma)
by intraperitoneal injection. VIN and M2 were dissolved in corn
oil at room temperature, prepared fresh weekly, and injected at a
dose of 50 milligrams/kilogram of body weight/day (mg/kg/d) at a
volume of 5 ul per gram of body weight. To reduce potential of lin-
eage effects confounding the treatment effects, we avoided placing
sibling females in the same treatment group and stud males were
used across treatment groups. Mice were treated daily from GD9.5
to GD18.5. At PND5 for G1 pups, dams and pups and were trans-
ferred to standard rodent chow (Teklad 8604) where they remained
throughout subsequent breeding until the end of the study.
We performed two separate rounds of study. For both rounds of
study, all methods of treatment and breeding schemes are main-
tained except where described (Fig. 1). Study 1 compared the effects
of VIN and M2 to CON between two genetic lineages (crossed
dam × sire): B6xC7 and 8nrCGxC7. G0 dams for these crosses were
either homozygous wild-type (B6) or homozygous mutant 8nrCG
mice. Study 2 compared the effects of VIN to CON among 5 genetic
crosses (dam × sire): B6xC7, 8nrCGxC7, C7x8nrCG, IVSxC7, and
2,3xC7. G0 dams for these crosses were either homozygous wild-
type (B6 and C7) or heterozygous mutant 8nrCG, 2,3, IVS mice.

































ig. 1. Treatment Scheme. Illustrates timing of crosses, special diets, experimental tre
omozygous mutant animals are indicated with “hom”, heterozygous mutant anim
o treatments in utero. F, female; M, male; DPreC, days precoitus.
.3. Body weight, body composition and anogenital distance
easurements
Body weight at PND5, PND28, and PND56 was measured by
nalytical balance. Body composition was measured by magnetic
esonance imaging (EchoMRI-100) at PND28 and PND56 in the
NC Nutrition Obesity Research Center Animal Metabolism Phe-
otyping Core (UNC NORC AMP). Percent fat and lean mass were
alculated using the ratio of fat or lean mass/(total body mass − free
ater mass) × 100. AGD was measured using calipers. Mice were
eighed at AGD measurement and changes in AGD due to body
eight changes were adjusted for using a ratio of AGD/body weight.
.4. Sperm isolation and count
Intact cauda epididymis and vas deferens were isolated from
ND84 males immediately after euthanasia in 1 ml of HTF buffer
pH7.5, 100 mM NaCl, 5 mM KCl, 0.368 mM KH2PO4, 0.2 mM MgSO4,
mM CaCl2 and 5 mg/ml BSA) at 37 ◦C and scored in 4-well petri
ishes under a dissection microscope. Scored tissues were incu-
ated for 10 min at 37 ◦C for sperm swim out. Sperm in supernatant
as transferred to fresh 1.5 ml microcentrifuge tubes and 3 ul were
sed in a 1:50 dilution of phosphate buffered saline (PBS) while
emaining cells were pelleted by centrifugation, flash frozen in liq-
id nitrogen and stored at −80 ◦C. Sperm counts and purity was
easured in the 1:50 dilution using a hemocytometer and inverted
ight microscope.
.5. Methylation detection & genotyping
Genomic DNA from sperm, tongue, and abdominal fat was iso-
ated using phenol-chloroform extraction [34] and from liver using
he Anaprep 12, an automated magnetic-bead based nucleic acid
xtraction system (BioChain Institute Inc, CA). DNA quality was
ssessed by NanoDrop 2000 spectrometer (Thermo Scientific, DE)
nd double stranded DNA concentrations measured by Quant-it
icoGreen dsDNA assay (#P7589, Life technologies, NY). Genomicnts, and phenotypes measured. Cross descriptions are shown in order female × male.
dicated with “het”. Asterisks (*) indicate which parental G1 animals were exposed
DNA was bisulfite-converted using the EZ DNA methylation Gold
kit according to the manufacturer’s protocol (#D5006, Zymo
research, CA). All pyrosequencing PCR and sequencing primers
and sequenced regions were confirmed to be devoid of SNPs or
deletions. Pyrosequencing was performed using Pyromark Q96MD
instrument according to the manufacturers’ instructions (Qiagen,
MD). Assays for Igf2DMR1 and H19PP were previously described
[21]. H19ICR Rp1 assays methylation at the H19/Igf2 ICR using
primers forward 5′- GAGGTATAAGAATTTTGTAAGGAGATTATG-3′
and biotinylated reverse 5′- ACTAAACTTAAATAACCCACAACATTAC-
3′ and pyrosequenced using primer 5′- ATTAGTTGTGGGGTT-3′.
PCRs for each sample and locus were performed in duplicate and
CpG methylation was determined by pyrosequencing. The aver-
age methylation of all CpGs combined within the assayed region
are presented as mean methylation (%) and used in all down-
stream analysis. The number of CpGs assayed for each region was
3 (Igf2DMR1), 6 (H19Rp1), and 3 (H19PP).
Sex of G1 offspring was confirmed by SRY amplification using
primers forward 5′- TTGTCTAGAGAGCATGGAGGGCCATGTCAA-3′
and reverse 5′-CCACTCCTCTGTGACACTTTAGCCCTCCGA-3′ [35].
2.6. Statistical analyses
Least squares linear regression was performed separately for
each genetic line with adjustment for sex and genotype where
applicable using the JMP Pro software version 13.0 (SAS, NC) to
compare among treatment groups for phenotypes in study 1 G1
phenotypes (litter size, % male, litter survival, PND56 AGD/body
weight, PND5 body weight, PND28 body weight, PND28% fat mass,
PND28% lean mass, liver H19ICR Rp1, Igf2DMR1 and H19PP methy-
lation, and abdominal fat and tongue H19ICR Rp1 methylation);
and G2 phenotypes (litter size, % male, PND5 body weight, PND5
kidney weight/body weight, and PND5 liver weight/body weight);
and phenotypes in study 2 (adult body weight and sperm methy-
lation at H19/Igf2). Treatment effects with p < 0.1 were assessed
further using Dunnett’s test to compare CON to either VIN or M2.
Correlations between sperm H19ICR Rp1 methylation and body
Fig. 2. G0 cross reproductive outcomes (Study 1). (A) Bar graph of average litter size at birth (top panel) and average percent of males in each litter (% male, bottom panel).
Each dot represents data for one litter. Dashed horizontal lines represent expected litter size and expected proportion of males for B6 litters. (B) Box and whiskers plot of
percent of pups in each litter that survived to weaning. Error bars indicate standard error of the mean (SEM). Treatment group(s) with a significant difference from CON is
d show



































enoted by (†). Sample sizes for each treatment group are listed from left to right as
t PND5 N = 5, 4, 4, 7, 3, 8; litter survival to weaning (N = 5, 4, 4, 9, 5, 13). Reduction
t PND5.
eight were determined separately for each genetic line by Spear-
an correlation using the JMP Pro software version 13.0 (SAS, NC).
tatistical analyses to compare between treatment groups for study
G1 phenotypes (PND56 body weight, PND56 percent fat mass,
ND56 percent lean mass, sperm count, liver and sperm methy-
ation levels at H19/Igf2 ICR) were performed using linear mixed
ffects models with fixed effects for treatments and random effect
or litter using the nlme package in R [36,37]. For all models, we
djusted for sex where applicable and compared the difference
etween CON and either VIN or M2 for each line. Benjamini-
ochberg (BH) correction [38] was used to adjust p-values (adj.p)
or multiple comparisons within each dataset and a false discovery
ate of 0.1 was used as the significance threshold.
. Results
.1. Phenotypic effects of in utero VIN exposure are genetic
ine-dependent
To determine whether the underlying genetic sequence at
he site of an epimutation influences phenotypic and epigenetic
esponse to VIN, we first compared the effects of in utero VIN expo-
ure in offspring from wild-type inbred B6 females to offspring
rom homozygous mutant 8nrCG females (both crossed to wild-
ype inbred C7 sires, Fig. 1). Pregnant mice were treated in three
eparate groups with either corn oil (CON), VIN dissolved in corn oil
VIN) or M2 dissolved in corn oil (M2), from GD9.5 to GD18.5 (Fig. 1).
his is a critical period in which the fetus undergoes gonadal sex
etermination, genome wide epigenetic reprogramming, imprint
stablishment at ICRs, and widespread developmental changes
39–41].
.1.1. Cross reproductive outcomes
To assess the effect of treatment on reproductive outcomes,
e measured litter size, sex ratio and pup survival to weaning.
or B6 mice, litter size, sex ratios and pup survival to weaning
ere not significantly affected by treatment with either VIN nor
2 (Fig. 2A and B). VIN treatment in 8nrCG mice did not signifi-
antly affect litter size or sex ratio (Fig. 2A). However, M2 treatmentn in each graph (N = number of litters): litter size at birth N = 5, 4, 4, 9, 5, 13; % male
etween litter size and% male reflects death of whole litter before pups were sexed
in 8nrCG mice was linked to a significant increase in litter size
(42%, p = 0.044, adj.p = 0.099) (Fig. 2A). Interestingly, M2 had the
lowest average in percent of males per litter (26.4% compared to
47.5% for CON) but this was not statistically significant (p = 0.105,
adj.p = 0.189). We assessed further whether males were dispropor-
tionately dying perinatally or inaccurately sexed due to feminized
features. We found no direct correlation between litter size and
proportion of males in the 8nrCG M2 group and sex misdetermi-
nation was ruled out by SRY genotyping. Compared to B6, 8nrCG
crosses exhibited a substantial difference in survival to weaning
(p = 0.010, adj.p = 0.084) with a high rate (9/28 litters) of whole lit-
ter mortality in the 8nrCG crosses (Fig. 2B). There was no significant
difference in gestational weight at GD18.5 or weight gain from
GD9.5-GD18.5 between B6 and 8nrCG mice (p = 0.412, p = 0.810,
respectively) making additional prenatal lethality unlikely. Par-
tial litter mortality in the 8nrCG mice resulted in the death of
an additional 18 pups, 15 of which died before the animals were
sexed at PND5. Postnatal mortality in the 8nrCG mice was simi-
lar across all treatment groups (Fig. 2B), and was not correlated
with male/female ratios (p = 0.148) indicating that male and female
offspring exhibited similar levels of postnatal mortality.
3.1.2. G1 body weight & body composition outcomes
To assess the effect of in utero treatment on adult phenotypes,
we measured adult (PND56) body weight and body composition
as growth/developmental endpoints. B6 mice showed no signifi-
cant difference in PND56 body weight for VIN or M2 treatment
groups (Fig. 3A). However, VIN-treated 8nrCG mice had signifi-
cantly higher PND56 body weight (3.6 g,18% increase on average,
p = 0.0008, adj.p = 0.024), while M2-treated mice were unaffected
(p = 0.718, adj.p = 0.886) (Fig. 3A). Male and female adult offspring
were affected similarly (Fig. 3A). The increase in VIN-treated 8nrCG
bodyweight was present as early as PND28 (1.8 g, 12%, p = 0.0018,
adj.p = 0.0273) but not detected at PND5 (Supplemental Fig. 1A &
B).To determine whether the increase in body weight in the 8nrCG
line was related to a change in body composition (disproportionate
increase in fat or lean mass), we compared percent fat and lean mass
(tissue mass/(body mass − free water mass)) between treatments
Fig. 3. G1 body weight and body composition outcomes (Study 1). PND56 (A) body weight; (B) percent fat mass; (C) percent lean mass. Top panels show bar graph of average
body weight for both sexes combined. Bottom panel is enlarged to only show portion y-axis covered by data points. Individual (dots) weights are separated by sex, male
(filled dots), female (unfilled dots); lines connect means between groups for males (solid line) or females (dashed line). Error bars indicate standard error of the mean (SEM).
F noted
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, female; M, male. Treatment group(s) with a significant difference from CON is de
n each graph (n = number of mice, both sexes combined; N = number of litters): PND
0, 16, 43; N = 5, 4, 5, 5, 3, 6; PND56% lean mass n = 28, 19, 26, 20, 16, 43; N = 5, 4, 5,
nd genetic lines. Percent fat mass was significantly increased
t PND28 for VIN-treated 8nrCG mice (15% increase, p = 0.019,
dj.p = 0.0988) (Supplemental Fig. 1C). However, by PND56, per-
ent fat mass was not significantly increased for any treatment
roup in either B6 or 8nrCG lineage (p = 0.248, adj.p = 0.623 and
= 0.083, adj.p = 0.313, respectively) (Fig. 3B). Percent lean mass
as not significantly changed for any treatment group for either
ineage either at PND28 or PND56 (Fig. 3C & Supplemental Fig. 1D).
aken together, these data suggest that the increase in adult bodyby (†). Sample sizes for each treatment group are listed from left to right as shown
dyweight n = 28, 19, 26, 27, 17, 50; N = 5, 4, 5, 7,3, 7; PND56% fat mass n = 28,19, 26,
.
weight is likely due to developmental phenotype that persisted into
adulthood and though changes in adiposity may play a role, this
is not the main driver of this phenotype. Since these effects were
only observed in VIN-treated mice, and not M2, they likely occur
independent of antiandrogenic activity.3.1.3. G1 reproductive development outcomes
To determine whether the antiandrogenic activity of VIN and
M2 reported previously, is sufficient to alter reproductive devel-
Fig. 4. G1 reproductive development outcomes (Study 1). Box and whiskers plot shown for PND56 (A) male AGD (normalized to body weight, top panel) and female AGD
(normalized to body weight, bottom panel); (B) PND84 total sperm count. Error bars indicate standard error of the mean (SEM). Treatment group(s) with a significant
d ted fr























ifference from CON is denoted by (†). Sample sizes for each treatment group are lis
= number of litters): PND56 male AGD/bodyweight n = 16, 11, 16, 14, 11, 16; N =
ND84 sperm count (n = 15, 11, 16, 13, 10, 13; N = 5, 4, 5, 5, 3, 5).
pment and male fertility in this model, we compared adult
GD and sperm count between genetic lineages and treatment
roups. After normalization to body weight (AGD/body weight),
6 males and females did not exhibit any significant differences
n PND56 AGD in either VIN or M2 treatment groups (Fig. 4A). On
he other hand, 8nrCG males exhibited a significant decrease in
ND56 AGD in the M2 treatment group (19% decrease, p = 0.0014,
dj.p = 0.024) (Fig. 4A), while females were not significantly affected
p = 0.070, adj.p = 0.298) (Fig. 4A). There were no statistically signif-
cant changes in sperm count for either genetic lineage or treatment
roup (Fig. 4B). These data show that in this model of VIN and
2 exposure, antiandrogenic effects on reproductive development
ere minimal and unlikely to affect fertility. M2 exposure had a
reater effect on reproductive development compared to VIN (as
xpected based on previously reported antiandrogenic activity),
ig. 5. G1 methylation outcomes at H19/Igf2 locus (Study 1). (A) Schematic of H19/Igf2 im
nd H19PP (locations indicated by horizontal bars below the domain). (B) Box and whi
epresents the mean methylation of 6 CpGs across the region analyzed for each individ
etween G1 sperm H19ICR Rp1 methylation levels and 12wk body weight. Treatment grou
reatment group are listed from left to right as shown in each graph (n = number of mice, b
0, 10, 9, 11, 10; N = 5, 4, 5, 4, 3, 5.om left to right as shown in each graph (n = number of mice, both sexes combined;
, 6, 3, 6; PND56 female AGD/bodyweight n = 12, 8, 10, 13, 6, 34; N = 5, 4, 5, 5, 3, 7;
and 8nrCG mice were more susceptible than B6. Importantly, it
confirms that body weight changes detected in the VIN treatment
group are not linked to antiandrogenic activity.
3.2. VIN-induced body weight increase is independent of
methylation state at H19/Igf2
The VIN dose used in this study (50 mg/kg/d) was previously
reported to alter DNA methylation state at the H19/Igf2 locus in
sperm of FVB/N mice [17]. To test whether the body weight sen-
sitivity of 8nrCG mice to VIN exposure is due to methylation
perturbation at the mutated H19/Igf2 locus, we compared methy-
lation state at 3 loci across the H19/Igf2 imprinted domain between
B6 and 8nrCG lineages treated with VIN or M2. These loci were
selected due to proximity to the 8nrCG mutation at the H19/Igf2 ICR
printed domain and loci assayed for methylation changes: Igf2DMR1, H19ICR Rp1,
skers plots of percent methylation at H19ICR Rp1 in G1 sperm samples; each dot
ual sample. Error bars indicate standard error of the mean (SEM). (C) Correlation
p(s) with a significant difference from CON is denoted by (†). Sample sizes for each
oth sexes combined; N = number of litters): Sperm H19ICR Rp1 Methylation n = 10,
Fig. 6. G1 male adult body weight and methylation outcomes across 5 genetic lines screened for VIN sensitivity (Study 2). (A) Bar graph of average adult (8–9 wks) body
weight (top panel) and box and whiskers plots of percent methylation at H19ICR Rp1 in G1 sperm samples (bottom panel); (B) Bar graph of same data shown in (A) but figure




















1, offspring from 8nrCG but not B6 dams exhibited a significant
increase in body weight in the VIN treatment group compared toON is denoted by (†). Sample sizes for each treatment group are listed from left to
itters): Adult body weight n = 4, 3, 7, 8, 9, 12, 5, 16, 9, 9; N = 2, 2, 3, 3, 3, 4, 2, 4, 4, 4;
H19ICR Rp1) and proximity to differentially methylated regions
DMR) linked to expression of Igf2 (Igf2DMR1) and H19 (H19PP).
e found that methylation levels in adult male liver were not
ffected by genetic lineage or treatment groups for any of the 3 loci
ested (Supplemental Fig. 2A). A small but statistically significant
ecrease in methylation was detected in 8nrCG VIN sperm at the
19ICR Rp1 (1%, p = 0.012, adj.p = 0.099) (Fig. 5B). Sperm methyla-
ion at H19ICR Rp1 was seemingly related to body weight in 8nrCG
nd not B6 mice, but this relationship was not statistically signif-
cant after correction for multiple testing (p = 0.025, adj.p = 0.139)
Fig. 5C). Methylation at H19ICR Rp1 in tongue (muscle) or abdomi-
al fat in 8nrCG mice was not affected by treatment (Supplemental
ig. 2B). In sum, these data suggest that individuals may have shared
usceptibility to VIN-induced body weight and sperm methylation
hanges. However, body weight differences are likely not directly
riven by methylation differences at the H19/Igf2 locus in 8nrCG
ice, thus another mechanism is at play.as shown in each graph (n = number of mice, genotypes combined; N = number of
H19ICR Rp1 methylation n = 5, 3, 5, 9, 10, 6, 5, 16, 8, 5; N = 2, 2, 2, 3, 3, 3, 2, 4, 4, 3.
3.3. VIN-induced outcomes are 8nrCG specific and due to a
maternal effect and not pup genotype
To determine whether VIN-induced phenotypic and epigenetic
outcomes observed in the 8nrCG mutant mouse line are caused by
genetic mutations at the H19/Igf2 ICR, we screened a panel includ-
ing two additional H19/Igf2 ICR mutant lines. We compared the
response of adult male offspring from heterozygous 8nrCG, 2,3,
IVS, and wild-type B6 dams (all crossed to C7 males) and offspring
from the reciprocal cross C7 dams × 8nrCG males (to determine
parent of origin dependence) (Fig. 1).
When comparing 8–9wk old male body weights and methyla-
tion at the H19/Igf2 ICR in sperm between VIN and CON-treated
mice across the panel of mice, we reproduced the 8nrCG lineage
specific VIN-induced effects observed in study 1. Similar to studyCON (3 g, 14% increase, p = 0.002, adj.p = 0.020) (Fig. 6A). However,
sperm methylation at the H19/Igf2 ICR in VIN-exposed offspring
Fig. 7. G2 offspring reproductive and birth outcomes at PND5 (Study 1). Asterisks (*) indicates treated parent(s). (A) Bar graph of average litter size (top panel) and% of litter
born male (bottom panel). (B) Bar graph of average body weight (top panel); kidney weight/normalized to body weight (middle panel); and liver weight/normalized to body
weight (bottom panel). (C) Samples separated by sex, male (M, filled dots) and female (F, unfilled dots) (top panel); or separated by genotype, wildtype (+/+,unfilled dots),
heterozygous mutant (+/−, filled dots), and homozygous mutant (−/−, grey dots) (bottom panel); lines connect means between treatment groups for sexes (top panel) or
genotypes (bottom panel). Error bars indicate standard error of the mean (SEM). Treatment group(s) with a significant difference from CON is denoted by (†). Sample sizes
for each treatment group are listed from left to right as shown in each graph (n = number of mice, genotypes combined; N = number of litters): Litter size N = 5, 2, 7, 8, 5, 9, 4,









, 3; % male N = 5, 2, 7, 8, 5, 7, 4, 3, 3; PND5 Body weight n = 32, 16, 44, 40, 36, 43, 31
6, 31, 20, 15; N = 2, 2, 4, 5, 5, 6, 5, 3, 3; PND5 Liver weight/Body weight n = 13, 16, 3
rom 8nrCG dams showed a similar trend but was not statistically
ignificant after correction for multiple testing, possibly due to the
maller sample size reducing power to detect such a small change
1%, p = 0.031, adj.p = 0.103). Although we could not statistically
est due to small sample size, both 8nrCG offspring genotypes (+/+
nd −/ + ) were on average affected similarly for body weight and
ethylation (Fig. 6B). Neither B6 nor the other mutant mice (2,35; N = 5, 2, 6, 7, 5, 7, 5, 3, 3; PND5 Kidney weight/Body weight n = 13, 16, 32, 23, 36,
36, 37, 31, 20, 15; N = 2, 2, 4, 6, 5, 6, 5, 3, 3.
and IVS) were affected by treatment (Fig. 6A). VIN-exposed off-
spring from 8nrCG sires (reciprocal cross, C7 × 8nrCG) were also
unaffected (Fig. 6A). We conclude that the VIN-induced methyla-
tion and body weight changes are likely due to an 8nrCG lineage
specific effect that was only observed when the mother carried an


























































.4. Paternal VIN exposure in utero decreases pup neonatal body
eight in a cross-dependent manner
VIN exposure was previously shown to result in heritable phe-
otypes [8,16,18]. Therefore, we determined whether paternal (G1)
IN exposure in utero alters unexposed second generation offspring
ody weight or epigenetic outcomes. To determine whether the
xposed male germline was sufficient to transmit any VIN-induced
ffects, we compared offspring from study 1 G1 males generated
y intercross (to treated G1 females) or outcross (to untreated B6
emales) (Fig. 1).
.4.1. Cross reproductive outcomes
There were no statistically significant reductions detected in lit-
er size or sex ratio associated with treatment group or genetic
ineage for either intercross or outcross groups (Fig. 7A). Therefore,
n support of data described above, G1 male and female fertility
ere not substantially affected by VIN or M2 treatment in utero.
.4.2. G2 growth/developmental outcomes
After adjustment for pup sex and genotype, we found that
2 neonatal (PND5) body weight was only significantly different
or pups from VIN-treated 8nrCG outcrossed sires compared to
ON sires (approx. 420 mg, 14%, p = 0.0025, adj.p = 0.035) (Fig. 7B).
lthough we could not statistically test due to small sample size,
oth 8nrCG offspring genotypes (+/+ and −/+) and sexes were on
verage affected similarly for body weight (Fig. 7C). Differences in
ody weight for 8nrCG outcross pups is likely due to differences
n growth and not adiposity since kidney and liver showed similar
ecreases in weight that were completely normalized after cor-
ection for body weight (Fig. 7B). Similar to our findings in the
arental mice, VIN-related changes in G2 8nrCG neonatal (PND5)
ody weight did not coincide with methylation changes at the
19/Igf2 ICR (Supplemental Fig. 3) as one might expect for a loss of
mprinting-related growth phenotype. PND5 body weight, kidney
nd liver weight (after normalization to body weight) was not sig-
ificantly different from CON for any other lineages or treatments
Fig. 7B). Taken together, these data demonstrate that first genera-
ion in utero exposure to VIN can alter second generation offspring
evelopment when transmitted through the paternal germline in
manner seemingly independent of antiandrogenic activity but
trongly influenced by genetic lineage and crossing scheme.
. Discussion
Here, we use several genetic mouse lines carrying mutations at
he H19/Igf2 ICR to assess the effect of genetic sequence differences
n phenotypic and epigenetic response to VIN exposure during fetal
evelopment. We found that compared to wild-type B6 mice, the
nrCG mutant line was more susceptible to VIN-induced changes
n body weight, body composition and H19/Igf2 ICR methylation.
mportantly, we reproduced the body weight finding and showed
hat these changes were seemingly independent of sex and pup
enotype at the H19/Igf2 ICR. Furthermore, assessment of recip-
ocal crosses showed that a maternal effect specific to the 8nrCG
ine was likely responsible for VIN-induced effects since they were
resent when offspring from 8nrCG dams were assessed but not
hen 8nrCG sires were used. We cannot rule out that maternal
enotype at the H19/Igf2 ICR is still responsible, but this seems
nlikely since none of the other mutant lines that exhibit greater
oss of imprinting at H19/Igf2 were significantly affected [20,21]. It
s possible that 129/SvJ loci in the <2% of the genome that remains
fter backcrossing to B6 are responsible. We also showed that in
tero VIN treatment in one generation altered body weight in a
econd generation but significant changes were only detected in
he 8nrCG lineage and specifically when mice were outcrossed toan unexposed female. Thus, contrary to expectation, intercross-
ing schemes may actually mask intergenerational effects. Overall,
these data show that even small differences in maternal genetic lin-
eage confer significant susceptibility to phenotypic and epigenetic
effects of environmental exposures in utero and therefore care-
ful attention should be taken in study design to control for such
features.
We were unable to replicate previous findings of sperm methy-
lation changes at the H19/Igf2 ICR associated with VIN exposure
[17]. This could be explained by either a strain effect or an aggregate
effect of other environmental factors such as diet. We did detect a
very small change (∼1%) in G1 sperm methylation associated with
VIN in the 8nrCG lineage. No methylation differences were detected
in second generation pups. It is very unlikely that the 1% methyla-
tion change in itself is biologically relevant or causative of any of
the phenotypes observed in either generation tested. However, the
correlation between sperm methylation and body weight in the
first generation suggests the two may be somehow physiologically
linked. We propose that both sperm methylation changes and body
weight differences associated with VIN are separate and indirect
outcomes of perturbation of gross development that likely began in
utero at the time of treatment. 8nrCG crosses exhibited increased
perinatal lethality, and although it was not linked to treatment,
it may allow for increased susceptibility to such developmental
perturbation when exposed to VIN in utero. Further studies are
required to dissect the pathways responsible.
In our assessment of the effects of VIN compared to effects
of the M2 metabolite, we found that offspring exposed to M2
behaved more similarly to CON-treated animals for almost all of the
phenotypes tested except those related to male reproductive devel-
opment. Even then, there were only minimal antiandrogenic effects
on male reproductive development. This was surprising since M2
has generally been shown to have greater antagonistic activity as
a ligand for steroid receptors including AR and ER [13]. However,
it does demonstrate that the effects of VIN reported here are likely
independent of such activity and confirms previous studies that
could not replicate VIN effects using flutamide [42]. Since our sam-
ple sizes here are somewhat modest, the lack of effect of the M2
treatment group also presents as a secondary control in this study
showing that the effects we observe are likely specific to VIN and
not due to random variation in the population. This is true for out-
comes in both generations and genetic lineages.
5. Conclusions
These data show that VIN may alter other important devel-
opmental pathways in a manner independent of antiandrogenic
function and that genetic strain sensitivity can have a significant
effect on outcomes. While VIN may not be of particular concern
as a toxicant due to restricted use in many countries, these data
are highly relevant for similar dicarboximide fungicides such as
iprodione that are still widely used in the US [43] as well as other
common EDCs. Studies determining the effects of EDC exposure for
safety and risk assessment purposes will benefit significantly from
comparing effects on different genetic lineages.
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